title: Phase II trial of trimetrexate in patients with advanced renal cell carcinoma. Clinical Community Oncology Program.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, Solid Tumor Service, New York, NY 10021.
authors.forename: C N
authors.initials: CN
authors.lastname: Sternberg
authors.forename: A
authors.initials: A
authors.lastname: Yagoda
authors.forename: H
authors.initials: H
authors.lastname: Scher
authors.forename: G
authors.initials: G
authors.lastname: Bosl
authors.forename: D
authors.initials: D
authors.lastname: Dershaw
authors.forename: K
authors.initials: K
authors.lastname: Rosado
authors.forename: C
authors.initials: C
authors.lastname: Houston
authors.forename: R
authors.initials: R
authors.lastname: Rosenbluth
authors.forename: V
authors.initials: V
authors.lastname: Vinciguerra
authors.forename: B
authors.initials: B
authors.lastname: Boselli
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004341:Drug Evaluation; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D011799:Quinazolines / Q000627:therapeutic use*; D016597:Trimetrexate
chemical_list: D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D011799:Quinazolines; D016597:Trimetrexate